First Manhattan CO Jounce Therapeutics, Inc. Transaction History

First Manhattan CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $16,800 - $46,020	-6,000 Reduced 48.39%	6,400 $19,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $131,040 - $226,980	-26,000 Reduced 67.71%	12,400 $92,000
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $35,672 - $57,848	-5,600 Reduced 12.73%	38,400 $268,000
Q3 2019 Nov 13, 2019	SELL	$3.33 - $4.93 $99,900 - $147,900	-30,000 Reduced 40.54%	44,000 $146,000
Q2 2018 Aug 01, 2018	SELL	$7.27 - $21.88 $29,080 - $87,520	-4,000 Reduced 5.13%	74,000 $566,000
Q4 2017 Jan 22, 2018	BUY	$12.52 - $17.82 $588,440 - $837,540	47,000 Added 151.61%	78,000 $994,000
Q3 2017 Oct 25, 2017	BUY	$11.17 - $16.99 $346,270 - $526,690	31,000	31,000 $482,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.